In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child ...

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company pioneering a novel gene editing platform to overcome drug resistance in solid tumors, today announced the publication of a ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

Drug resistance has long turned some of the most advanced lung cancer therapies into temporary victories, with tumors ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...